Patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab-bevacizumab treatment were more likely to experience variceal bleeding if they had a low platelet count, main portal ...
Relevance section written by JCO Associate Editor Gary K. Schwartz, MD, FASCO. The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in patients with advanced solid tumors. Presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback